Summary: Study questions whether smell loss associated with COVID-19 infection may increase the risk of developing dementia later in life.
A review of studies about the effect of SARS-CoV-2—the virus that causes COVID-19—on the olfactory system introduces questions about whether loss of smell associated with COVID-19 infection may increase the risk of developing dementia later in life.
The review is published ahead of print in the Journal of Neurophysiology (JNP).
Loss of smell (anosmia) is one of the hallmark symptoms associated with the first wave of COVID-19 in 2020, with an estimated 77-85% of people infected with the virus reporting loss or alteration of smell (parosmia).
Although most people recover quickly from this dysfunction, an estimated 15 million people around the world are considered “smell long haulers” after otherwise recovering from COVID-19. They experience persistent anosmia or parosmia.
Studies have shown that the olfactory sensory epithelium—located in the upper area of the nose, close to where the olfactory nerve enters the olfactory bulb in the brain—carries a high viral load in people infected with SARS-CoV-2.
The olfactory bulb is the structure in the brain that manages the sense of smell and sends sensory information to other areas of the brain for processing. These other brain regions are involved with learning, memory and emotion.
“All of this means that the [olfactory bulb] is involved in much more than smelling. It’s involved in the sense of place, memory, context, emotion, reward and many other processes,” said Leslie M. Kay, Ph.D., author of the review.
Due to the proximity of the olfactory sensory epithelium to the olfactory bulb, COVID-19 infection could affect cognitive function even after recovery. A correlation between disrupted sense of smell and dementia has also been found in some people with neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease. Animal studies have shown that damage to the bulb results in anxiety and a depression-like state.
“Previous pandemics also lend support to the theory that “viral invasion of the [central nervous system] can be a trigger for neurodegeneration resulting in later neurological deficit,” Kay explained. The 1918 Spanish influenza pandemic led to a wave of people who developed Parkinson’s disease, and data from Denmark find that people who have had the flu have a 70% higher risk of developing Parkinson’s disease a decade later.
“The review offers evidence that suggests inflammation introduced to the olfactory nerve and damage to the olfactory bulb via COVID-19 infection and immune response may also cause degeneration of brain structures connected to the olfactory system and cognitive impairment.
More research is needed and is possible due to the technological advances available to scientists during the current pandemic,” Kay said.
“While a catastrophe on many levels, the COVID-19 pandemic presents an opportunity to improve human health.”
About this COVID-19 and dementia research news
OriginalResearch: Open access.
“COVID-19 and olfactory dysfunction: a looming wave of dementia?” by Leslie M. Kay et al. Journal of Neurophysiology
COVID-19 and olfactory dysfunction: a looming wave of dementia?
Olfactory dysfunction is a hallmark symptom of COVID-19 disease resulting from the SARS-CoV-2 virus.
The cause of the sudden and usually temporary anosmia that most people suffer from COVID-19 is likely entirely peripheral – inflammation and other damage caused by the virus in the sensory epithelium inside the upper recesses of the nasal cavity can damage or prevent chemicals from properly activating the olfactory sensory neurons.
However, persistent olfactory dysfunction from COVID-19, in the form of hyposmia and parosmia (decreased or altered smell) may affect as many as 15 million people worldwide.
This epidemic of olfactory dysfunction is thus a continuing public health concern. Mounting evidence suggests that the SARS-CoV-2 virus itself or inflammation from the immune response in the nasal sensory epithelium may invade the olfactory bulb, likely via non-neuronal transmission. COVID-19 related long term olfactory dysfunction and early damage to olfactory and limbic brain regions suggests a pattern of degeneration similar to that seen in early stages of Alzheimer’s, Parkinson’s and Lewy Body dementias.
Thus, long term olfactory dysfunction coupled with cognitive and emotional disturbance from COVID-19 may be the first signs of delayed onset dementia from neurodegeneration.
Few treatments are known to be effective to prevent further degeneration, but the first line of defense against degeneration may be olfactory and environmental enrichment.
There is a pressing need for more research on treatments for olfactory dysfunction and longitudinal studies including cognitive and olfactory function from patients who have recovered from even mild COVID-19.